Exploring Novel Hallmark of Aging Targeting Strategies & Defining Quantitative Endpoints to Enhance Translatability & Clinical Success
Welcome to the 6th Age-Related Disease Therapeutics Summit
Demonstrating Clinical Promise with Quantitative Endpoints to Extend Healthy Lifespan
In 2024, age-related disease biotechs are set to shine, building on 2023's milestones such as Eli Lilly's partnership with BioAge to test muscle rejuvenation therapy and Chan Zuckerberg Biolabs tapping into immune cell engineering to eradicate age-related diseases.
To successfully navigate the volatile market of 2024, rapid proof-of-concept studies and validated clinical endpoints are crucial for funding and pipeline progress.
The 6th Age-Related Disease Therapeutics Summit is returning to San Francisco in June, with 60+ participants including Eli Lilly, Takeda, and Turn Biosciences to dive deep into breakthroughs in cellular programming, senolytic pathways, and epigenetic effects. Explore biomarkers, navigate regulations, and foster collaborations for pipeline support and commercialization.
This is your definitive age-related disease therapeutics forum to gain unparalleled competitive intelligence, scientific advancements and form meaningful partnerships to solve humankind’s fundamental problem.
60+
Attendees
1
Workshop Day
20+
Expert Speakers
3
Content Filled Days
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
“The breadth and depth of the presentations was outstanding. There was little repetition whilst remaining entirely on point with respect to the mechanisms underlying aging and longevity. Absolutely outstanding speakers.”
Marilda Chung, Cureline, Inc.
Other Events in the Series:
